CRISPR Therapeutics AG at Goldman Sachs Healthcare Conference Transcript
Good afternoon. Thank you, everyone, for joining us. We're really pleased to have with us CRISPR Therapeutics. And with me, I have Raju Prasad, CFO.
Questions & Answers
Raj, could you start by giving us a brief overview of where your portfolio stands today, your updated strategic focus on the cardiovascular and autoimmune franchise? And how you're thinking about technologies as you bring in new modalities, including [siRNA] and in vivo CAR-T?
Yes, absolutely. And thank you for having us at the Goldman conference once again, and it's great to be here. CRISPR is now over 12 years old, we're entering sort of our teen years as a company. And with that, in addition to CASGEVY, which is our approved product with commercial partner in Vertex, which I'm sure we'll talk about; we really have been focusing on the pipeline and identifying what our next
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
